Allakos — Investor Presentation (June 2022)
53 slides from Allakos's investor presentation, Jun 21, 2022
Slide 1: Corporate Presentation June 2022
Corporate Presentation June 2022 Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Disease Exhibit 99.1
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. (“Allakos,” the “Company,” “we” or “our”); the generation of future value; b
Slide 3: Novel Targets for the Treatment of Inflammatory Diseases
Novel Targets for the Treatment of Inflammatory Diseases Lirentelimab (anti-Siglec-8) mAb that has potent eosinophil depletion and inhibits mast cells Lirentelimab Active & Well Tolerated Molecule AK006 (anti-Siglec-6) mAb that selectively and potently inhibits mast cells, including KIT-mediated sig
Slide 4: Mast Cells and Eosinophils Are Key Drivers of Inflammatory Disease
Mast Cells and Eosinophils Are Key Drivers of Inflammatory Disease IL-13
Slide 5: Allakos Pipeline
Antibody Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Registration Milestone Atopic Dermatitis Initiated 4Q 2021; Topline expected 2H 2023 Chronic Spontaneous Urticaria Initiation mid-2022; Topline expected 2H 2023 EoD: EoDyssey Topline data expected Q3 2022 EG and/or EoD: ENIGMA
Slide 6: Significant Opportunity Exists to Treat Inflammation & Immunology
Significant Opportunity Exists to Treat Inflammation & Immunology Rheumatoid Arthritis Psoriasis Ulcerative Colitis Crohn’s Disease Asthma Atopic Dermatitis Chronic Spontaneous Urticaria Eosinophilic Gastrointestinal Disorders 2021 Estimated WW Sales ~$30 bn ~$24 bn ~$8 bn ~$14 bn ~$8 bn ~$5 bn ~$0.
Slide 7: Lirentelimab: Siglec-8 mAb That Depletes Eosinophils and Inhibits Mast Cells
Lirentelimab: Siglec-8 mAb That Depletes Eosinophils and Inhibits Mast Cells
Slide 8: Lirentelimab: Siglec-8 mAb That Depletes Eosinophils and Inhibits Mast Cells
Lirentelimab: Siglec-8 mAb That Depletes Eosinophils and Inhibits Mast Cells Lirentelimab shows eosinophil depletion and mast cell inhibition in humans: Rapid and complete depletion of eosinophils via ADCC Inhibition of mast cell activation via multiple stimuli including IL-33, TSLP, IgE, MRGPRX-2,
Slide 9: Sustained Depletion of Blood Eosinophil Counts
Sustained Depletion of Blood Eosinophil Counts Phase 2 ENIGMA1 Study and Open-Label Extension Time on Treatment (Weeks)b Dose Eosinophilsa (Cells/µL) Median ±IQR 800 500 250 0 BL 56 53 55 53 53 55 53 50 48 46 44 44 36 33 n SOURCE: Dellon ES, et al. New England Journal of Medicine. 2020;383:1624-1634
Slide 10: Lirentelimab Broadly Inhibits Mast Cell Activation
Lirentelimab Broadly Inhibits Mast Cell Activation Lirentelimab Inhibits IL-33-Mediated Mast Cell Activation Transcriptome of IL-33-Activated Mast Cells Phospho-Proteome of IgE-Activated Mast Cells SOURCE: Schanin, J et al. Mucosal Immunology. 2020: 366-376 SOURCE: Korver, W et al. Frontiers in Immu
Slide 11: Lirentelimab for Atopic Dermatitis
Lirentelimab for Atopic Dermatitis
Slide 12: Biopsies of Atopic Dermatitis Lesions Show Evidence of Mast Cell and Eosinophil Activity
Biopsies of Atopic Dermatitis Lesions Show Evidence of Mast Cell and Eosinophil Activity Immune Cell Numbers Disease Biomarkers Mast Cell Activation CCL26 / Eotaxin-3 CCL17 / TARC CPA3 Eosinophils Mast Cells SOURCE: Youngblood, BA et al JCI Insights 2019: 126219; Schanin, J et al Mucosal Immunology
Slide 13: Lirentelimab Reduced Cytokines in Phase 1 Severe Allergic Conjunctivitis Study
Lirentelimab Reduced Clinically-Relevant Cytokines in Phase 1 Severe Allergic Conjunctivitis Study SOURCE: Anesi, S. et al. Journal of Allergy and Clinical Immunology 2022 Ocular Inflammation via Tear Cytokines Last Dose Last Dose Last Dose Last Dose IL-4 IL-13 CCL26 / Eotaxin-3 CCL3 / MIP-1
Slide 14: Lirentelimab Improved Atopic Dermatitis Symptoms in ENIGMA2 and SAC Studies
Lirentelimab Improved Atopic Dermatitis Symptoms in ENIGMA2 and SAC Studies Median % Change from BL Weeks 21-22 Placebo (n=4) Lirentelimab (n=5) Atopic Dermatitis (Open-Label SAC Study) Lirentelimab (n=11) Atopic Dermatitis (ENIGMA2) SOURCE: ENIGMA2 data on file, Post-hoc exploratory analysis; SAC S
Slide 15: Phase 2/3 Atopic Dermatitis Study Design
Phase 2 Atopic Dermatitis Study Design Multi-center, randomized, DB, placebo-controlled Chronic disease that has been present ≥3 years EASI score ≥16 Involvement of ≥10% of body surface area IGA score ≥3 Inadequate control by topical treatments Includes patients with prior biologics treatment 130 ad
Slide 16: Atopic Dermatitis Landscape
Atopic Dermatitis Landscape Drug Name MOA EASI-75 Response IGA Response Opportunity Dupixent® (Dupilumab) Anti IL-4/IL-13R mAb 44 – 51% vs. 12 – 15% placebo1 36 – 38% vs. 9 – 10% placebo1 >50% of patients continue to have symptoms Conjunctivitis in ~26%1 Q2W dosing1 Adbry™ (Tralokinumab) Anti IL-13
Slide 17: Lirentelimab for Chronic Urticaria
Lirentelimab for Chronic Urticaria
Slide 18: Phase 2a Chronic Urticaria Study
Phase 2a Chronic Urticaria Study Open-label study in patients with Chronic Urticaria (CU) Uncontrolled CU (UCT <12) at the time of enrollment Diagnosis of CU for at least three months, refractory to antihistamine treatment on 1 to 4x labeled dosage 45 patients – 4 cohorts Omalizumab-naïve Chronic Sp
Slide 19: Symptom Improvement by UAS7 with Lirentelimab in CSU
Symptom Improvement by UAS7 with Lirentelimab in CSU Omalizumab Naïve (n=13) Baseline Week 22 Omalizumab Refractory Receiving All 6 Doses (n=7) UAS7 is a validated patient-reported outcome recording the intensity of pruritus (Weekly Itch Severity Score) and the number of wheals (Weekly Hives Severit
Slide 20: Lirentelimab UAS7 Results in Patients with CSU
Endpoint Baseline Omalizumab Naïve Week 22 Average UAS7 Score 18.5 4.6 (-75%) Patients with UAS7 ≤ 6 0 (0%) 8/13 (62%) Patients with UAS7 = 0 0 (0%) 7/13 (54%) Patients with ISS7 = 0 0 (0%) 7/13 (54%) Patients with HSS7 = 0 0 (0%) 10/13 (77%) Lirentelimab UAS7 Results in Patients with CSU UAS7 is a
Slide 21: High UCT Response Rate Observed in Multiple Forms of Urticaria
High UCT Response Rate Observed in Multiple Forms of Urticaria Indication UCT Baseline UCT Complete Responders Chronic Spontaneous Urticaria Naïve (n=13) Xolair Refractory (n=7)1 3.2 3.1 92% 57% Cholinergic Urticaria (n=11) 5.4 82% Symptomatic Dermographism (n=10) 5.7 40% Urticaria Control Test (UCT
Slide 22: Safety Risk Profile Summary
Safety Risk Profile Summary No drug-related serious adverse events observed Most common adverse event (AE) was mild to moderate infusion-related reactions (IRRs) (flushing, feeling of warmth, headache, nausea, or dizziness) 36% IRRs rate on first infusion 6% IRRs rate on subsequent infusions SOURCE:
Slide 23: Phase 2b Chronic Spontaneous Urticaria Study
Phase 2b Chronic Spontaneous Urticaria Study Multi-center, randomized, DB, placebo-controlled Active moderate-to-severe symptoms CSU diagnosis with onset ≥6 months prior to screening Diagnosis of CSU refractory to antihistamines Presence of itch and hives despite current use of antihistamines UAS7 s
Slide 24: Chronic Spontaneous Urticaria Landscape
Chronic Spontaneous Urticaria Landscape Drug Name MOA UAS7 Response Opportunity Xolair® (omalizumab) Anti-IgE mAb 150 mg1 300 mg1 Placebo1 >50% of patients continue to have symptoms Black box for anaphylaxis1 UAS7 -14.4 (-48%) -20.8 (-66%) -8.0 (-26%) UAS7=0 15% 36% 9% Dupixent® (Dupilumab) Anti IL-
Slide 25: Lirentelimab for Severe Allergic Conjunctivitis
Lirentelimab for Severe Allergic Conjunctivitis
Slide 26: Severe Allergic Conjunctivitis Phase 1b Study
Severe Allergic Conjunctivitis Phase 1b Study Open-label study in patients with SAC Diagnosis of AKC, VKC or PAC Average total ACS score of 15 or more from >14 daily questionnaires during 4-week screening 29 patients – 3 cohorts Atopic keratoconjunctivitis Vernal keratoconjunctivitis Perennial aller
Slide 27: Improvements in Allergic Conjunctivitis Signs & Symptoms
Improvements in Allergic Conjunctivitis Signs & Symptoms Median Total ACS Baseline Weeks 21-22 Median Total OSS Baseline Day 140 -71% -78% Patient Reported Investigator Assessment All Subjects (n=29) SOURCE: Anesi, S. et al. Journal of Allergy and Clinical Immunology 2022. Leonardi A, et al. EAACI 2
Slide 28: Improvements Observed Across Signs & Symptoms
Improvements Observed Across Signs & Symptoms Symptom Median % Δ from BL to Wk 21-22 Allergic Conjunctivitis Symptom (ACS) Patient Reported - Daily Itching -74% Light Sensitivity -57% Eye Pain -75% Foreign Body Sensation -80% Watering Eyes -76% Symptoms & Signs Median % Δ from BL to Day 140 Ocular S
Slide 29: Severe Allergic Conjunctivitis Safety Risk Profile Summary
Severe Allergic Conjunctivitis Safety Risk Profile Summary No drug related serious adverse events (SAEs) observed Most common adverse event was mild to moderate infusion-related reactions (IRRs; flushing, feeling of warmth, headache, nausea, or dizziness) 16.7% IRRs rate on first infusion 0.7% IRRs
Slide 30: Lirentelimab for Eosinophilic Gastrointestinal Disorders
Lirentelimab for Eosinophilic Gastrointestinal Disorders
Slide 31: Lirentelimab for Eosinophilic Gastrointestinal Disorders
Lirentelimab for Eosinophilic Gastrointestinal Disorders Eosinophilic Esophagitis (EoE) and Eosinophilic Gastritis and Eosinophilic Duodenitis (EG/EoD) are characterized by chronic inflammation of the gastrointestinal tract The Phase 2 study in EG and/or EoD (ENIGMA1) met all primary and secondary e
Slide 32: EGID Biopsies Have Elevated and Activated Eosinophils & Mast Cells
EGID Biopsies Have Elevated and Activated Eosinophils & Mast Cells Eosinophils and mast cells both appear to play a pathogenic role in EGIDs Lirentelimab is a novel investigational therapy that directly targets eosinophils and mast cells SOURCE: Youngblood B, et al. JCI Insights. 2019 Eosinophils 10
Slide 33: ENIGMA2 Phase 3 EG/EoD Study Design
ENIGMA2 Phase 3 EG/EoD Study Design Multi-center, randomized, DB, placebo-controlled Active moderate to severe symptoms Biopsy confirmed EG and/or EoD Stomach: ≥30 eos/high powered field (hpf) in 5 hpfs Duodenum: ≥30 eos/hpf in 3 hpfs 180 adult patients (1:1 randomization) Lirentelimab 1 + 3 + 3 + 3
Slide 34: ENIGMA2 Phase 3: Co-Primary Endpoints
ENIGMA2 Phase 3: Co-Primary Endpoints Histology Co-Primary Endpoint Symptom Co-Primary Endpoint Proportion of Patients Achieving EG/EoD Histologic Response1 at Week 24 1.) Eosinophil response criteria: ≤4 eos/hpf in top 5 gastric hpfs and/or ≤15 eos/hpf in top 3 duodenal hpfs. 2.) TSS6 Symptoms: abd
Slide 35: Patient Baseline Demographics & Characteristics: Site Comparison
Patient Baseline Demographics & Characteristics: Site Comparison Patient Characteristics Ph2 ENIGMA1 (E1) Ph3 ENIGMA21 Patient Characteristics n=65 E1 Sites n=81 Non-E1 Sites n=99 Age, median years (range) 40 (18-74) 45 (18-77) 40 (17-78) Female sex, % (n) 62% (40) 59% (48) 70% (69) History of EoE,
Slide 36: Mean Change in TSS6 from Baseline at End of Treatment
Mean Change in TSS6 from Baseline at End of Treatment1 1.) Retrospective sub-group analysis. ENIGMA1: mean TSS6 change from BL to Weeks 13-14; ENIGMA2: mean TSS6 change from BL to Weeks 23-24. *LS Means and p-values derived from ANCOVA/MMRM models Mean TSS6 Change from BL Placebo (n=20) Lirentelimab
Slide 37: ENIGMA2 Safety Risk Profile Summary
ENIGMA2 Safety Risk Profile Summary No drug-related Serious AEs Safety risk profile overall was consistent with previously reported safety risk profile in ENIGMA1 and other lirentelimab studies to date n (%) of Patients Lirentelimab (n=91) Placebo (n=89) ≥1 Treatment-Emergent Adverse Event (TEAE) 65
Slide 38: KRYPTOS Phase 2/3 EoE Study Design
KRYPTOS Phase 2/3 EoE Study Design Multi-center, randomized, DB, placebo-controlled Active moderate to severe symptoms Dysphagia Symptom Questionnaire (DSQ) ≥12 Biopsy confirmed EoE Esophagus: ≥15 eos/high power field (hpf) in 1 hpf 276 patients dosed (1:1:1 randomization) High dose lirentelimab 1 +
Slide 39: KRYPTOS Phase 2/3: Co-Primary Endpoints
KRYPTOS Phase 2/3: Co-Primary Endpoints Histology Co-Primary Endpoint Symptom Co-Primary Endpoint High Dose * (80/91) (86/93) Low Dose Lirentelimab * Placebo (10/92) % of Patients Proportion of EoE Eosinophil Responders (≤6 eos/hpf at Week 24) * Difference from placebo p-values <0.0001 derived using
Slide 40: Adolescents Demographics and Patient Characteristics
Adolescents Demographics and Patient Characteristics SOURCE: 1. Dellon ES, et al. Presentation at UEGW 2020; 2. Rothenberg ME, et al. Presentation at AAAAI 2022. A. Pooled data were estimated based on the data by arm presented; B. Asthma, allergic rhinitis, atopic dermatitis and/or food allergy; C.
Slide 41: Greater Activity Observed in Adolescents
Greater Activity Observed in Adolescents Pre-specified Analysis Absolute Change in DSQ at Weeks 23-24 Percent Change in DSQ at Weeks 23-24 *p=0.1316 Lirentelimab 34.1 34.6 35.2 BL DSQ = Placebo (n=16) High Dose (n=15) Low Dose (n=16) Lirentelimab Placebo (n=16) High Dose (n=15) Low Dose (n=16) *p=0.
Slide 42: KRYPTOS Safety Risk Profile Summary
KRYPTOS Safety Risk Profile Summary n (%) of Patients HD Lirentelimab (n=91) LD Lirentelimab (n=93) Placebo (n=92) ≥1 Treatment-Emergent Adverse Event (TEAE) 61 (67.0%) 65 (69.9%) 53 (57.6%) Infusion related reaction 35 (38.5%) 24 (25.8%) 11 (12.0%) Headache 6 (6.6%) 8 (8.6%) 6 (6.5%) Drug-related S
Slide 43: EoD Phase 3 Study Design
EoD Phase 3 Study Design Multi-center, randomized, double-blind, placebo-controlled study in EoD Active moderate to severe symptoms Biopsy confirmed EoD ± colonic involvement Duodenum: ≥30 eos/hpf in 3 hpfs Stomach: <30 eos/high powered field (hpf) in 5 hpfs (Do NOT have EG) Colonic involvement asse
Slide 44: AK006: Siglec-6 mAb that Selectively and Potently Inhibits Mast Cells
AK006: Siglec-6 mAb that Selectively and Potently Inhibits Mast Cells
Slide 45: AK006: Siglec-6 mAb That Inhibits and Depletes Mast Cells
AK006 is a humanized IgG1 agonistic Siglec-6 mAb that selectively inhibits mast cells and reduces their numbers: Represents the first mast cell-specific antibody in development Inhibition of both IgE-dependent and IgE-independent mast cell activation Reduction of mast cells via Fc-dependent mechanis
Slide 46: AK006 Shows High Association with Inhibitory Molecules
AK006 Shows High Association with Inhibitory Molecules Mast Cell Inhibition AK006 SHP-1 AK006/SHP-1
Slide 47: AK006 Inhibits Mast Cell Activation in Human Tissues
AK006 Inhibits Mast Cell Activation in Human Tissues IgE-Activated Human Tissue Mast Cells AK006 inhibits IgE-mediated mast cell activation Human Tissue Mast Cell Activation Assay n=3 human donors
Slide 48: AK006 Inhibits KIT-Mediated Mast Cell Activation in Siglec-6 Transgenic Mice
AK006 Inhibits KIT-Mediated Mast Cell Activation in Siglec-6 Transgenic Mice Mast Cell Activation AK006 inhibits KIT-mediated mast cell activation SCF, stem cell factor; * p < 0.01; n=7-8 mice/group Cytokines and Chemokines CD63 IL-6 TNF CXCL1 / GRO- CCL2 / MCP-1
Slide 49: AK006 Reduces IL-33-Mediated Skin Inflammation in Siglec-6 Transgenic Mice
AK006 Reduces IL-33-Mediated Skin Inflammation in Siglec-6 Transgenic Mice * p < 0.01; n=6 mice/group AK006 inhibits IL-33-mediated inflammation via MC inhibition and reduction Immune Cell Infiltration in Skin Day 0 ISO or AK006 Day 2 Immune cell infiltration in ear Intradermal IL-33 injection IL-33
Slide 50: AK006 Inhibits Allergic Contact Dermatitis in Siglec-6 Transgenic Mice
AK006 Inhibits Allergic Contact Dermatitis in Siglec-6 Transgenic Mice Skin Inflammation AK006 reduces skin inflammation * p < 0.01; n=6-7 mice/group DNFB, 2,4-dinitrofluorobenzene Cytokines in Ex Vivo-Cultured Ears
Slide 51: Financial Overview & Key Milestones
Financial Overview & Key Milestones
Slide 52: Balance Sheet and Significant IP Protection
Balance Sheet and Significant IP Protection Cash, Cash Equivalents and Investments in Marketable Securities as of March 31, 2021 $246.7 M Common Shares Outstanding 54.7 M First Lirentelimab US patents to expire in 2035 without extensions or additional IP Commercial manufacturing already established
Slide 53: Allakos Pipeline
Antibody Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Registration Milestone Atopic Dermatitis Initiated 4Q 2021; Topline expected 2H 2023 Chronic Spontaneous Urticaria Initiation mid-2022; Topline expected 2H 2023 EoD: EoDyssey Topline data expected Q3 2022 EG and/or EoD: ENIGMA